Efficacy and Safety of Clearing Heat and Detoxifying Injection in the Treatment of Influenza: A Randomized, Double-Blinded, Placebo-Controlled Trial
Table 3
Decline of total symptoms severity scores in the group itself and between two groups.
Time
group
PO − PR (95% CI)
In the group itself
T − C (95% CI)
Between groups
-test
-value
-test
value
Day 2
T
24
9.90 ± 5.30 (8.89, 10.91)
19.40
<0.0001
1.20 ± 0.67 (−0.11, 2.52)
4.18
0.042
#
C
22
8.70 ± 4.58 (7.84, 9.55)
20.09
<0.0001
Day 3
T
24
14.84 ± 5.21 (13.85, 15.84)
29.62
<0.0001
0.09 ± 0.67 (−1.24, 1.42)
0.02
0.888
C
22
14.75 ± 4.79 (13.85, 15.65)
32.57
<0.0001
Day 6
T
24
19.41 ± 4.48 (18.55, 20.26)
44.99
<0.0001
0.64 ± 0.61 (−0.56, 1.84)
1.21
0.272
C
22
18.77 ± 4.57 (17.91, 19.62)
43.43
<0.0001
T: treatment group (CHDI); C: control group (oseltamivir); PR − PO, posttreatment score minus prior treatment score; . Mean ± SD, T − C: treatment group score minus control group score, and #significant difference between groups.
